Drugs / NY-ESO-1
NY-ESO-1
also known as
peptide vaccine · Eso-1 · L antigen family member 2 · Lage-2 · NY-ESO-1 157-165 (165V) · NY-ESO-1 Protein Vaccine · Ny-eso-1(157-170)
Trials 15 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT00874861 | Apr 2009 → May 2012 | astrocytoma (excluding glioblastoma), oligoastrocytoma, oligodendroglioma | Ian F. Pollack, M.D. | Completed | No outcome recorded |
| Phase 16 trials | ||||||
| Phase 1 | NCT01810016 | Jan 2014 → May 2016 | metastatic melanoma | Ludwig Institute for Cancer Research | Terminated | No outcome recorded |
| Phase 1 | NCT01176474 | Aug 2010 → Aug 2020 | cutaneous melanoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT01176461 | Aug 2010 → Dec 2016 | cutaneous melanoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT00471471 | Oct 2008 → Dec 2011 | conjunctival cancer, cutaneous melanoma, ocular melanoma | Ahmad Tarhini | Completed | No outcome recorded |
| Phase 1 | NCT00299728 | Mar → Oct 2006 | neoplasm | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 1 | NCT00142454 | Aug 2005 → Apr 2006 | melanoma | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT01584115 | Jul 2012 → Jul 2013 | lung cancer, melanoma, ovarian cancer | Instituto de Investigação em Imunologia | Unknown | No outcome recorded |
| Phase 1/2 | NCT01079741 | Sep 2010 → Mar 2013 | melanoma | Nina Bhardwaj | Completed | No outcome recorded |
| Phase 1/2 | NCT01308294 | Jun 2010 → Apr 2014 | melanoma | Centre Hospitalier Universitaire Vaudois | Terminated | No outcome recorded |
| Phase 1/2 | NCT02429440 | May 2005 → Oct 2017 | renal cell carcinoma | University Hospital Tuebingen | Unknown | No outcome recorded |
| Phase 1/2 | NCT02452307 | Apr 2004 → Oct 2017 | prostate carcinoma | University Hospital Tuebingen | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02802943 | Oct 2016 → Sep 2022 | chronic lymphocytic leukemia/small lymphocytic lymphoma | University Hospital Tuebingen | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00090493 | Jun 2004 → Jul 2007 | plasma cell myeloma | University of Arkansas | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00694551 | Dec 2008 → Feb 2013 | prostate cancer | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
Press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-11-10 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Announcement of Termination of Co-Development and Exclusive MarketingAgreements with Takara Bio for NY-ESO-1・siTCR gene therapy candidate ® otsuka.co.jp ↗ |
| 2020-06-24 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Clinical program for NY-ESO-1/siTCR gene therapy candidate receives designation in Japan as Orphan Regenerative MedicineTM otsuka.co.jp ↗ |
| 2019-02-14 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Designation Description Change of NY-ESO-1・siTCRTM gene therapy product under "SAKIGAKE Designation System" otsuka.co.jp ↗ |
| 2018-04-09 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka enters agreement with Takara Bio for co-development and sales rights in Japan to NY-ESO-1 siTCRTM and CD19 CAR gene therapies otsuka.co.jp ↗ |
| 2014-06-06 | Gilead Sciences | Kite Pharma Announces Exclusive License with The National Institutes of Health for T Cell Receptor (TCR)-Based Products Targeting NY-ESO-1 For Multiple Cancer Indications gilead.com ↗ |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NY-ESO-1 | “syringe 1 containing NA-17, MAGE-3.A2 and NY-ESO-1 peptides with IMP321/LAG3 ± Montanide” NCT01308294 ↗ |
| Known as | Eso-1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594483 ↗ |
| Known as | L antigen family member 2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594483 ↗ |
| Known as | Lage-2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594483 ↗ |
| Known as | NY-ESO-1 157-165 (165V) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01176474 ↗ |
| Known as | NY-ESO-1 Protein Vaccine | “Biological: NY-ESO-1 Protein Vaccine” NCT01810016 ↗ |
| Known as | Ny-eso-1(157-170) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594483 ↗ |
| Known as | peptide vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02429440 ↗ |
| Modality | Protein / enzyme biologic | “NY-ESO-1 recombinant protein mixed with CpG 7909 and Montanide ISA-51 VG” NCT00299728 ↗ |
| Route | Subcutaneous | “The vaccinations was to be administered subcutaneously every 3 weeks for 4 doses.” NCT00299728 ↗ |